- Prospectus filed pursuant to Rule 424(b)(3) (424B3)

Filed Pursuant to Rule 424(b)(3)
File No. 333-163132

INHIBITEX, INC.

PROSPECTUS SUPPLEMENT NO. 1

TO THE PROSPECTUS DATED DECEMBER 2, 2009

This Prospectus Supplement No. 1 supplements our prospectus dated December 2, 2009.

The purpose of this prospectus supplement is to amend the “Selling Stockholders” section beginning on page 18 of the prospectus dated December 2, 2009 in order to reflect the transfer by Biomedical Value Fund, L.P., a selling stockholder of a portion of the Warrants held by it to its affiliate, Biomedical Institutional Value Fund, L.P.

The attached information modifies and supersedes, in part, the information in the prospectus. Any information that is modified or superseded in the prospectus shall not be deemed to constitute a part of the prospectus except as modified or superseded by this prospectus supplement.

This prospectus supplement is not complete without, and may not be delivered or utilized except in connection with, the prospectus, including any amendments or supplements thereto.

Investing in our common stock involves a high degree of risk. See “Risk Factors” beginning on page 3 of the Prospectus, as supplemented by this Prospectus Supplement and any of our other filings incorporated therein by reference.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is April 2, 2010

ADDITION OF SELLING STOCKHOLDERS

The information relating to Biomedical Value Fund, L.P. in the selling stockholder table in the section of the prospectus entitled “Selling Stockholders,” beginning on Page 18 of the prospectus, is updated as set forth below. The table below also sets forth, as of the date of this prospectus supplement, the name of the additional selling stockholder, the number of shares of our common stock, par value $0.01 per share, owned by such selling stockholder prior to the offering, the number of shares being offered by such selling stockholder under the prospectus, as amended by this prospectus supplement, and the number of shares to be owned by such additional selling stockholder if all of the shares offered by it under the prospectus, as amended by this prospectus supplement, are sold.

Number of

Shares

Number of Shares

Owned

Being Offered

Shares Owned

Prior to

Warrant

after Offering

Name

the Offering(1)

Shares

Number(2)

Percent

Biomedical Institutional Value Fund, L.P.

96,563

—

Biomedical Value Fund, L.P.

1,398,749

1,031,250

367,499

—


(1)		Includes shares which may be obtained upon the cash exercise of outstanding warrants that were either (a) issued to the selling stockholders on October 28, 2009 pursuant to the Stock and Warrant Purchase Agreements between the selling stockholders and us or (b) transferred to a selling stockholder from a selling stockholder described in clause (a).

(2)		Assumes the sale of all of the shares offered by this prospectus (including shares obtained upon the cash exercise of outstanding warrants that were either (a) issued to the selling stockholders pursuant to the Stock and Warrant Purchase Agreements or (b) transferred to a selling stockholder from a selling stockholder described in clause (a)).